Table 1. Details and results of certain phase III studies.

Trial	Recruitment	Stage	N patients	Total dose/fraction size (Gy)	RT technique	Local recurrence rate (%)	P	5-year survival rate (%)	P
Belgium (6)*	1966-1977	I, II (N0)	104	–	–	10.90	ns	43	<0.05 (no PORT)
			98	60/2	Cobalt	1.20		24
LCSG (12)	1978-1985	II, III	120	–	–	41	0.001	40	ns
			110	50.4/1.8	Cobalt and Linac	3		40
CAMS (11)	1981-1995	II, III	182	–	–	33.20	0.01	40.5	ns
			183	60/2	Cobalt and Linac	12.70		42.9
Lille (10)*	1985-1991	I	72	–	–	na	ns	51.6	ns
			60	45-60/2	Cobalt and Linac	na		35.2
GETCB (7) [86 and 88]	1986-1994	I, II, III	355	–	–	34	ns	43	0.002 (no PORT)
			373	60/2-2.5	Cobalt and Linac	28		30
Italy (15)*	1989-1997	I	53	–	–	23	0.019	58	0.048 (PORT)**
			51	50.4/1.8	Linac	2.20		67
Austria (16)		I, II, III	72	–	–	20	<0.01	20.4	ns
			83	50-56/2	Linac	7		29.7

*, pN0 patients; **, this result was no longer significant when updated (14)